Loratadine: Difference between revisions
| Line 23: | Line 23: | ||
**Do not exceed 10 mg in 24 hours | **Do not exceed 10 mg in 24 hours | ||
**The ODT formulation is not recommended for younger children. | **The ODT formulation is not recommended for younger children. | ||
===[[Urticaria]]=== | |||
*Children aged 6 and older | |||
**10 mg PO once daily | |||
***Some patients may benefit from higher doses. Clinicians should weigh the risks against the benefits. | |||
==Special Populations== | ==Special Populations== | ||
Revision as of 21:32, 20 May 2026
Administration
- Type: H1 antagonists (second generation)
- Dosage Forms: Tablets (chewable or orally disintegrating tablets [ODTs]), liquid-filled capsules, or a syrup (1 mg/mL solution)
- Routes of Administration: Oral
- Common Trade Names: Claritin
Adult Dosing
Allergic rhinitis
- 10 mg PO once daily, OR
- 5 mg twice daily
- Do not exceed 10 mg in 24 hours
Urticaria
- 10 mg PO once daily
- Some patients may benefit from higher doses. Clinicians should weigh the risks against the benefits.
Pediatric Dosing
Allergic rhinitis
- Children aged 6 and older
- 10 mg PO once daily, OR
- Children aged 2 to 5
- 5 mg PO once daily
- Do not exceed 10 mg in 24 hours
- The ODT formulation is not recommended for younger children.
Urticaria
- Children aged 6 and older
- 10 mg PO once daily
- Some patients may benefit from higher doses. Clinicians should weigh the risks against the benefits.
- 10 mg PO once daily
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion: